ライフサイエンスコーパス: therapeutic outcome

1 most judicious to achieve a highly effective therapeutic outcome.

2 that altering tumor metabolism could change therapeutic outcome.

3 tibody positivity was an immune biomarker of therapeutic outcome.

4 (CP) CML], correlates with subsequent poorer therapeutic outcome.

5 ause BACE1 elevation, a potentially negative therapeutic outcome.

6 D73 in cancer may be useful for an effective therapeutic outcome.

7 has a paracrine effect on tumorigenesis and therapeutic outcome.

8 K3 signaling pathways in CTCL to enhance the therapeutic outcome.

9 ptive lineage pre-specification may optimize therapeutic outcome.

10 e at treatment on Treg induction and optimal therapeutic outcome.

11 the impact of the tumor microenvironment on therapeutic outcome.

12 l characteristics, microbiological data, and therapeutic outcome.

13 ith an aggressive clinical course and a poor therapeutic outcome.

14 r of 11 biomarkers that were associated with therapeutic outcome.

15 ssion patterns and colon cancer prognosis or therapeutic outcome.

16 TNM staging, and was associated with a poor therapeutic outcome.

17 otypic plasticity and invasion and determine therapeutic outcome.

18 on is associated with poor survival and poor therapeutic outcome.

19 iation of alternative approaches, maximizing therapeutic outcome.

20 ther these parameters might be predictors of therapeutic outcome.

21 T/mBT immunotherapy correlates with a better therapeutic outcome.

22 propagation, ultimately leading to enhanced therapeutic outcome.

23 d be a powerful firsthand tool for assessing therapeutic outcome.

24 erfere with CTL responses and compromise the therapeutic outcome.

25 equires innovative new approaches to improve therapeutic outcome.

26 ug metabolism mediated by cytochrome P450 on therapeutic outcome.

27 arcinogenic exposure and/or to modulation of therapeutic outcome.

28 lophosphamide relative to mAb is critical to therapeutic outcome.

29 associated with macrophage infiltration and therapeutic outcome.

30 icted to have the most significant effect on therapeutic outcome.

31 l other groups, in association with improved therapeutic outcome.

32 set and vector delivery, probably impact the therapeutic outcome.

33 to determine potential clinical relevance in therapeutic outcome.

34 and, by some criteria, it attenuates rIL-12 therapeutic outcome.

35 etic resonance imaging methods for measuring therapeutic outcome.

36 5 kinases using ON123300 results in a better therapeutic outcome.

37 ling tailored therapy regimens and enhancing therapeutic outcome.

38 transfused platelets, preventing the desired therapeutic outcome.

39 ial selective pressures, affecting long-term therapeutic outcome.

40 ubtle differences among these systems on the therapeutic outcome.

41 morigenesis and can have opposing effects on therapeutic outcome.

42 r chemistry is linked with biological and/or therapeutic outcome.

43 an effective strategy to improve the drug's therapeutic outcome.

44 re still not adequate to provide the desired therapeutic outcome.

45 ess and metastatic evolution with underlying therapeutic outcomes.

46 ic pathways demonstrated to mediate observed therapeutic outcomes.

47 expedite CD4(+) T-cell recovery and improve therapeutic outcomes.

48 ms of prophylaxis failure that could improve therapeutic outcomes.

49 ogical biases can be attributed to different therapeutic outcomes.

50 nical sequencing and translation to improved therapeutic outcomes.

51 DA dysfunction may be helpful in predicting therapeutic outcomes.

52 radigm shift with significant improvement in therapeutic outcomes.

53 its and would improve cost-effectiveness and therapeutic outcomes.

54 sed therapeutic decisions and better predict therapeutic outcomes.

55 nto the importance of material properties on therapeutic outcomes.

56 trategies, and provide an objective index of therapeutic outcomes.

57 ment, respectively, and may result in better therapeutic outcomes.

58 are necessary to prevent relapse and improve therapeutic outcomes.

59 might also be involved in the modulation of therapeutic outcomes.

60 53 should be considered to achieve favorable therapeutic outcomes.

61 consistent and reliable cross comparisons of therapeutic outcomes.

62 expression could be correlated with distinct therapeutic outcomes.

63 een examined as they relate to prognosis and therapeutic outcomes.

64 measured and effectively targeted to improve therapeutic outcomes.

65 hus enabling tailored therapy strategies and therapeutic outcomes.

66 blood-brain barrier is important for optimal therapeutic outcomes.

67 aucoma medications and caution in evaluating therapeutic outcomes.

68 d, and improvement of patient compliance and therapeutic outcomes.

69 s been a proven clinical strategy to enhance therapeutic outcomes.

70 nostimulation and improves drug delivery and therapeutic outcomes.

71 otherapy, optimal doses are a key factor for therapeutic outcomes.

72 and mitigate factors that contribute to poor therapeutic outcomes.

73 embrane transporters are key determinants of therapeutic outcomes.

74 reward, motivation, and learning to improve therapeutic outcomes.

75 an additional specific role for Ly6E in poor therapeutic outcomes.

76 ion in patients with RP are needed to assess therapeutic outcomes.

77 ease state to achieve optimal diagnostic and therapeutic outcomes.

78 ll needed to improve prognostic accuracy and therapeutic outcomes.

79 d of course the heart itself for appropriate therapeutic outcomes.

80 r-associated fibroblasts (TAFs) for improved therapeutic outcomes.

81 d drug resistance and therefore offer better therapeutic outcomes.

82 inical risk groups of tumours with different therapeutic outcomes.

83 and negative GFN blocks in association with therapeutic outcomes.

84 edly influence systemic exposure and thereby therapeutic outcomes.

85 inical practice with improved diagnostic and therapeutic outcomes.

86 of antibody-cytokine complexes for improved therapeutic outcomes.

87 y cancer with few treatment options and poor therapeutic outcomes.

88 ons recorded shortly after therapy predicted therapeutic outcomes 6 mo later, which involved persiste

89 TRAIL apoptosis signaling and better cancer therapeutic outcomes act through this pathway.

90 th MAPK and PI3K/AKT pathways offer a better therapeutic outcome against ATC.

91 novirus (oAd/DCN/LRP) to achieve a desirable therapeutic outcome against pancreatic cancer.

92 kinetics obfuscates the relationship between therapeutic outcome and administered dose, thereby imped

93 by chemotherapy could substantially improve therapeutic outcome and patient survival.

94 tivity of malignant cells seems to influence therapeutic outcome and patients' survival.

95 ion and noninvasive monitoring would improve therapeutic outcome and reduce unnecessary toxicities.

96 A balance between therapeutic outcome and undesirable side effects must be

97 e attend to both DCS effects on facilitating therapeutic outcomes and additional therapeutic mechanis

98 ally applicable system that is predictive of therapeutic outcomes and is useful for the execution and

99 ce liquid chromatography and correlated with therapeutic outcomes and toxicities attributable to ganc

100 ive to mAb administration is critical to the therapeutic outcome, and although the combination can im

101 tanding pathogenic mechanisms, evaluation of therapeutic outcomes, and screening new vaccines.

102 ciated with a high Sokal score predictive of therapeutic outcome are normalized in patients in molecu

103 gnostic tool, but solid criteria for optimal therapeutic outcomes are lacking.

104 Because therapeutic outcomes are so closely tied to disease phas

105 Issues including morbidity, cost and therapeutic outcomes are, however, important considerati

106 that not only impacts tumor development, but therapeutic outcome as well.

107 ts and other specialists increase successful therapeutic outcomes" as second most important.

108 as typically measured by drug surrogate, and therapeutic outcome, as determined by clinically relevan

109 mportant implications for not only improving therapeutic outcomes, but also maximizing the clinical u

110 ITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition W

111 patients from Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition W

112 ITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN w

113 ndrome in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition w

114 IMI 38 study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition w

115 tality in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition W

116 rvention, the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition W

117 sugrel in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition W

118 ITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition w

119 months in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition W

120 The Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition W

121 dogrel in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition w

122 ITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN w

123 In agreement with the observed therapeutic outcome, centrocyte subtypes were estimated

124 ognitive health is a critical determinant of therapeutic outcome, chemobrain remains an unmet medical

125 elivery followed by ablation showed the best therapeutic outcome compared with all other treatment gr

126 r-specific antibody to significantly enhance therapeutic outcomes compared with immunocytokine monoth

127 presentation, presence of malformations, and therapeutic outcome, could be documented.

128 proach that combines genomic, proteomic, and therapeutic outcome datasets to identify novel putative

129 However, a successful therapeutic outcome depends not only on the activity of

130 cute lymphoblastic leukemia (ALL) has a poor therapeutic outcome despite attempts to treat it based o

131 with TPV and BOC is critical for optimizing therapeutic outcomes during hepatitis C treatment.

132 onse, coupled with the improved experimental therapeutic outcome following IL-2 administration, sugge

133 enously and noninvasively control and refine therapeutic outcomes following cell transplantation.

134 The therapeutic outcome for unresectable, locally advanced,

135 odulation as a potential strategy to improve therapeutic outcome for use of hCPCs in patients with HF

136 potential to improve prognostic accuracy and therapeutic outcomes for breast cancer patients.

137 Current therapeutic outcomes for breast cancer underscore the co

138 ntravascular stents has resulted in improved therapeutic outcomes for coronary artery disease.

139 n this population may lead to more effective therapeutic outcomes for fatty liver.

140 Therapeutic outcomes for patients with brain metastases

141 pcidin regulation may contribute to improved therapeutic outcomes for patients with genetic and acqui

142 esults provide a monitoring system to assess therapeutic outcomes for PD.

143 mises to yield novel approaches to improving therapeutic outcomes for PTSD and other anxiety and trau

144 Clinical evaluations of therapeutic outcome from SCC DBS were defined at 6 month

145 Therapeutic outcomes from several psychotropic drugs hav

146 Assessment of therapeutic outcomes has been difficult, primarily becau

147 how tumour clonal heterogeneity impacts upon therapeutic outcome, however, is still an area of unmet

148 l CD4+ effector cells, resulting in improved therapeutic outcome in a mouse lymphoma model.

149 anoreporter technology that is predictive of therapeutic outcome in individual subjects.

150 mulative toxicity, may result in an improved therapeutic outcome in ovarian cancer.

151 antibiotic susceptibility testing to predict therapeutic outcome in patients infected with Mycobacter

152 lecules ex vivo is crucial for improving the therapeutic outcome in patients with HF.

153 ne is thus identified to be a determinant of therapeutic outcome in PDT of tumors.

154 nvestigated activity of cytochrome P450s and therapeutic outcome in people with cancer.

155 ct pretreatment clinical characteristics and therapeutic outcome in previously untreated adult APL pa

156 n profiles are associated with prognosis and therapeutic outcome in several human cancers.

157 ed and, at least in theory, will improve the therapeutic outcome in terms of local tumour control and

158 ars useful to stage objectively and evaluate therapeutic outcome in the management of gastric, low-gr

159 e an opportunity for functional repair and a therapeutic outcome in the wake of ischemic injury.

160 ing mAb cetuximab (Erbitux) greatly improved therapeutic outcomes in a metastatic model of EGFR-posit

161 ical chemoresistance and potentially improve therapeutic outcomes in AML.

162 to confer even nanodopant packing, improving therapeutic outcomes in bone repair by remarkably improv

163 ne kinase inhibitors could improve long-term therapeutic outcomes in CD25-positive AML.

164 of factors that contribute to heterogeneous therapeutic outcomes in clinical trials.

165 ty to TMZ, providing a strategy for improved therapeutic outcomes in GBM patients.

166 In addition, the therapeutic outcomes in M3-9-M tumor models correlated w

167 enuate neuroinflammation may greatly improve therapeutic outcomes in models of perinatal white matter

168 gnificance: Epigenomic targeting may improve therapeutic outcomes in platinum-resistant and recurrent

169 into perspective and weighed against actual therapeutic outcomes in prospective clinical trials.

170 regards to the long-term clinical course and therapeutic outcomes in these patients.

171 g the basal systemic inflammatory status and therapeutic outcomes in this cohort.

172 tions, clinical patient characteristics, and therapeutic outcomes in this large cohort of uniformly t

173 One potential cause of this suboptimal therapeutic outcome is that changes in the neural activi

174 In order to improve therapeutic outcomes it is recommended to monitor IFX tr

175 lthough IFN-gamma played a major role in the therapeutic outcome, it was consistently found to be inf

176 When these cases were correlated with therapeutic outcome, it was found that 7 of the 12 patie

177 Because of the good therapeutic outcome, it was possible to extend the follo

178 These data indicate that the therapeutic outcome may be further augmented by tuning t

179 tumor subclone that may ultimately influence therapeutic outcome may evade detection because of its a

180 une responses, we hypothesized that improved therapeutic outcomes may be achieved by using oncolytic

181 uced, which probably contributed to the poor therapeutic outcome observed in the patient carrying the

182 ne IL-1Ra levels were associated with better therapeutic outcomes (odds ratio 1.82 [95% confidence in

183 n tumor-reactive CD8(+) T cells improves the therapeutic outcome of adoptive immunotherapy in a mouse

184 e conclude that both subsets may improve the therapeutic outcome of allogeneic T cell transfers in pa

185 based DNA adduct analysis for predicting the therapeutic outcome of anti-cancer agents, for monitorin

186 n of vancomycin or gatifloxacin improved the therapeutic outcome of B. cereus endophthalmitis.

187 lantation requires optimization for improved therapeutic outcome of CD133+ cell grafts in stroke.

188 strategy has a high potential to improve the therapeutic outcome of combined gene therapy and radioth

189 n synaptic proteins suggest that the desired therapeutic outcome of estrogen may be accomplished by u

190 HER2/ErbB2 signaling and is a determinant of therapeutic outcome of Herceptin-based therapy, which fu

191 The therapeutic outcome of limited PS combined with EPBD for

192 s indicate that CTLA-4 blockade improves the therapeutic outcome of low-dose L-PAM for MOPC-315 tumor

193 proach by which to predict the physiological/therapeutic outcome of M3-mAChR-biased ligands with impo

194 in regulating the progression, severity, and therapeutic outcome of metabolic diseases.

195 o standard chemotherapy does not improve the therapeutic outcome of older AML patients.

196 ositive effects on the safety as well as the therapeutic outcome of oncolytic virotherapy.

197 e case series have been published concerning therapeutic outcome of pallidal deep brain stimulation i

198 therefore, a high potential to increase the therapeutic outcome of the enzyme/prodrug strategy in ca

199 g-metabolizing enzymes, which impacts on the therapeutic outcome of the stated diseases.

200 These CPLs could improve the therapeutic outcome of vaccination strategies or can be

201 ic sites in the lung could radically improve therapeutic outcomes of a variety of lung diseases, incl

202 nically measurable enhancements on the final therapeutic outcomes of CAF in Miller's Class I recessio

203 Therapeutic outcomes of combination chemotherapy have no

204 h mainly involves keratinocytes, may improve therapeutic outcomes of current treatments.

205 Therapeutic outcomes of definitively treated non-small-c

206 point-of-care diagnostic tool for improving therapeutic outcomes of IBD patients.

207 ering clinical translation and assessment of therapeutic outcomes of NP delivery vehicles.

208 , XRCC1, ERCC1, XPD, and XRCC3 in predicting therapeutic outcomes of older adults with acute myeloid

209 ept for use of these novel agents to improve therapeutic outcomes of patients with mutant ALK-driven

210 e may play a crucial role in determining the therapeutic outcomes of SC injected biopharmaceuticals.

211 Importantly, therapeutic outcomes of some immunological treatments ar

212 lecular targets is clearly needed to improve therapeutic outcomes of this devastating human disease.

213 starts to make a significant contribution to therapeutic outcome once resistance has started to evolv

214 rrent standard-of-care results in a marginal therapeutic outcome, partly due to acquirement of resist

215 by which intra-tumoral heterogeneity impacts therapeutic outcome remain poorly understood.

216 of peristalsis is predictive of an improved therapeutic outcome requires further study.

217 atients were followed up and correlated with therapeutic outcome retrospectively.

218 Various techniques of improving therapeutic outcomes, such as dosimetric estimations, hi

219 P 24 h after 131I-B72.3 further improved the therapeutic outcome (T(q) = 48.5 +/- 7.9 d; P < 0.001) a

220 fibody ligands exhibit much better antitumor therapeutic outcomes than clinically approved liposomal

221 revention generally results in more positive therapeutic outcomes than post-diagnostic interventions,

222 tion is predicted to result in more positive therapeutic outcomes than post-diagnostic interventions,

223 id could lead to more robust and longer-term therapeutic outcomes than previously reported.

224 Current surgical interventions have limited therapeutic outcomes; therefore, methods that would allo

225 to derive gene expression models predicting therapeutic outcomes, though such efforts are costly, ti

226 ing microenvironment participate directly in therapeutic outcome through the wrapping of myelin aroun

227 rovide evidence that links TIL abundance and therapeutic outcome to the regulation of tumor glycolysi

228 es is therefore essential to further enhance therapeutic outcomes to enable widespread medical applic

229 complement receptor and an IgG Fc fragment, therapeutic outcome was improved in vivo.

230 bined with 1% ALN gel results in significant therapeutic outcomes when compared with PRF and access t

231 ne receptor signaling, leading to beneficial therapeutic outcomes while reducing side effect profiles

232 tro susceptibility methods was predictive of therapeutic outcome, while the results of cocultivation

233 ce mechanisms and of the role of immunity in therapeutic outcomes will support new approaches to drug

234 ly used to model human folate metabolism and therapeutic outcomes with antifolates.

235 facilitate subject-by-subject correlation of therapeutic outcomes with transgene expression and will

236 heduling of anti-PD-L1 mAb was important for therapeutic outcome, with concomitant but not sequential

237 arcinoma (PDAC) initiation, progression, and therapeutic outcome, yet the mechanistic underpinning of